4Front Ventures
Analyst Coverage
Cannabis Investor News in-house rating · cin-analyst-v1.0
CIN assigns 4Front Ventures a Neutral rating with 3/5 conviction, reflecting a 37.6 composite that lacks a sufficiently strong foundation for a directional call. The 49.0 regulatory pillar provides the principal support, led by a 50.0 jurisdiction score and an 80.0 enforcement subscore. The 40.0 market pillar offers secondary support, although institutional pricing feeds currently provide no quote. Fundamentals contribute only 31.0 as contracting sales, operating losses, minimal market capitalization scoring, and weak cash-runway characteristics offset a respectable gross-margin subscore. Editorial contributes 30.0 because CIN newsroom coverage recorded no newsroom or brief activity. The resulting profile fits the Neutral band: regulatory stability prevents an Underweight assessment, while financial strain blocks an Overweight rating.
Licensed fundamentals data show year-over-year revenue contracting by 25.5%, a decisive drag represented by a 24.5 revenue-growth subscore. Gross margin remains 35.6%, supporting the comparatively strong 59.3 gross-margin subscore, but the operating margin stands at negative 38.4%, confirming that gross profitability does not translate into operating leverage. Net income is a $36.4 million loss and EBITDA is negative $17.0 million, consistent with the stated stretched financial condition and a 15.0 cash-runway subscore. Primary regulatory filings show no latest filing date, producing a 25.0 cadence subscore despite no regulatory events across either the 90-day or 180-day periods and no enforcement hits. That combination explains why regulatory remains strongest without signaling comprehensive disclosure strength.
The clearest forward catalyst sits within the regulatory pillar rather than the operating model. A return to current, consistent primary regulatory filings would directly address the weakest component of the company’s strongest pillar, improve visibility into financial progression, and create a firmer basis for institutional pricing feeds and CIN newsroom coverage to register new information. Regulatory posture and the clean enforcement record already supply relative stability, but cadence remains the actionable variable capable of lifting conviction from the present 3/5 level. The single most important signal to watch is the appearance of a current primary regulatory filing that restores a measurable disclosure cadence.
- CEO
- Leo Go***r
- SEC CIK
- 0001783875
- Website
- Company website
- Market cap
- $0.0M
- Enterprise value
- $212.9M
- Price to book
- 3.31
- EV / EBITDA
- -258.86
- Revenue (TTM)
- $75.6M
- Gross profit (TTM)
- $26.9M
- EBITDA
- $-17.0M
- Operating margin
- -38.4%
- Profit margin
- -48.1%
- Rev growth YoY
- -25.5%
- Return on equity
- -182.7%
- Return on assets
- -5.1%
- EPS (TTM)
- $-0.11
- Wall St. target price
- $2.37
- Shares outstanding
- 913.9M
- Insider ownership
- 51.1%
- Institutional ownership
- 6.7%
- Beta
- 0.17
- Full-time employees
- 374
- GICS sector
- Healthcare
- GICS industry
- Drug Manufacturers - Specialty & Generic
- Filing portal
- SEC EDGAR
Help us keep coverage accurate. Submit an update for CIN editorial review.
Bullish and Bearish Analyst Opinions for 4Front Ventures (FFNTF)
Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for 4Front Ventures (FFNTF), a cannabis-sector equity listed on OTCMKTS. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.
CIN editorial stance: Risk Elevated. Headwinds: deep drawdown. (0 bullish signals, 2 bearish signals.)
Historical Price Data
5-year weekly price history, intraday quotes, and 52-week range for FFNTF are maintained by Cannabis Investor News and refreshed throughout the trading day.